| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
WAY 647802 targets cyclin-dependent kinases (CDKs), a family of serine/threonine kinases that play a critical role in cell cycle progression and transcriptional regulation. By inhibiting CDKs, WAY 647802 can induce cell cycle arrest and inhibit cell proliferation. The specific CDK isoforms targeted by WAY 647802 are not detailed in the available literature, but it is classified as a CDK inhibitor.
|
|---|---|
| ln Vitro |
In vitro, WAY 647802 is a potent CDK inhibitor. It inhibits CDK activity in enzyme assays, leading to reduced phosphorylation of CDK substrates. In cell-based assays, it induces cell cycle arrest and inhibits cell proliferation. However, specific IC₅₀ values and the precise CDK isoforms targeted are not extensively detailed in the available literature.
|
| ln Vivo |
In vivo, WAY 647802 has the potential to inhibit tumor growth in CDK-dependent cancers. However, specific in vivo efficacy data in animal models are not extensively detailed in the available literature. It is a research compound and is not approved for clinical use.
|
| Enzyme Assay |
In vitro CDK kinase assays for WAY 647802 are performed using purified recombinant CDK/cyclin complexes. The kinase is incubated with a peptide substrate and ATP in the presence of varying concentrations of WAY 647802. Phosphorylation is detected using a luminescence-based or fluorescence-based assay. IC₅₀ values are calculated from dose-response curves. Selectivity is confirmed by screening against a panel of kinases.
|
| Cell Assay |
In vitro cell-based assays for WAY 647802 are performed using cancer cell lines. Cells are cultured in appropriate media and treated with WAY 647802 at various concentrations for 48-72 hours. Cell viability is measured by MTT or CellTiter-Glo assays. Cell cycle analysis is performed by flow cytometry. Apoptosis is evaluated by caspase-3/7 activation and Annexin V/PI staining.
|
| Animal Protocol |
In vivo animal studies for WAY 647802 would typically involve mouse xenograft models of CDK-dependent cancers. Immunodeficient mice are injected with cancer cells to establish tumors. When tumors reach a certain size, WAY 647802 is administered intraperitoneally or orally. Tumor growth is measured over time. Pharmacodynamic studies assess CDK inhibition and cell cycle markers in tumor tissue.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic properties of WAY 647802, such as half-life and oral bioavailability, are not extensively detailed in the available literature. As a small molecule with a molecular weight of 250.25 g/mol, it is expected to have good oral bioavailability. It is soluble in DMSO (10 mM) and is typically formulated for in vivo administration.
|
| Toxicity/Toxicokinetics |
Comprehensive toxicological data for WAY 647802 are not widely available in public literature. As a research compound, it is intended for laboratory use only and is not for human therapeutic use. Standard safety precautions should be followed when handling this compound. The compound is supplied with a purity of ≥98%.
|
| Additional Infomation |
WAY 647802 is a novel and potent CDK inhibitor. It is also known as WAY-647802. It inhibits cyclin-dependent kinases, which are key regulators of the cell cycle. This product is for research use only.
|
| Molecular Formula |
C11H14N4O3
|
|---|---|
| Molecular Weight |
250.253861904144
|
| Exact Mass |
250.106
|
| Elemental Analysis |
C, 52.79; H, 5.64; N, 22.39; O, 19.18
|
| CAS # |
852225-20-8
|
| PubChem CID |
4780686
|
| Appearance |
Solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
511.3±50.0 °C at 760 mmHg
|
| Flash Point |
263.0±30.1 °C
|
| Vapour Pressure |
0.0±1.3 mmHg at 25°C
|
| Index of Refraction |
1.591
|
| LogP |
0.52
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
18
|
| Complexity |
323
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C)N1CCN(C2C=CC([N+](=O)[O-])=NC=2)CC1
|
| InChi Key |
XRKWOGZOQWSBCT-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H14N4O3/c1-9(16)13-4-6-14(7-5-13)10-2-3-11(12-8-10)15(17)18/h2-3,8H,4-7H2,1H3
|
| Chemical Name |
1-[4-(6-nitropyridin-3-yl)piperazin-1-yl]ethanone
|
| Synonyms |
WAY-647802; WAY 647802; WAY647802;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.9960 mL | 19.9800 mL | 39.9600 mL | |
| 5 mM | 0.7992 mL | 3.9960 mL | 7.9920 mL | |
| 10 mM | 0.3996 mL | 1.9980 mL | 3.9960 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
